acromegaly
Information
- Disease name
- acromegaly
- Disease ID
- DOID:2449
- Description
- "A disease of metabolism that has_material_basis_in excessive growth hormone production which results_in enlargement located_in limb." [url:http\://en.wikipedia.org/wiki/Acromegaly, url:http\://www.acromegaly.org/, url:http\://www.mayoclinic.com/health/acromegaly/DS00478, url:http\://www.nlm.nih.gov/medlineplus/ency/article/000321.htm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05431803 | Active, not recruiting | Real-World Study (RWS) of Lanreotide Autogel (LAN) for the Treatment of Patients With Acromegaly in China | June 30, 2022 | December 31, 2024 | |
| NCT03043586 | Active, not recruiting | Treatment Patterns and Treatment Outcomes for Acromegaly | December 2016 | July 2025 | |
| NCT04349839 | Active, not recruiting | ACRODAT Prospective Evaluation Study | January 15, 2020 | February 1, 2025 | |
| NCT04837040 | Active, not recruiting | Phase 3 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly | May 12, 2021 | June 2027 |
| NCT04125836 | Active, not recruiting | Phase 3 | A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | October 10, 2019 | June 2025 |
| NCT05364944 | Active, not recruiting | Phase 1 | A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | May 18, 2022 | December 2024 |
| NCT05192382 | Active, not recruiting | Phase 3 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | December 17, 2021 | January 2028 |
| NCT04261712 | Active, not recruiting | Phase 2 | A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) | January 29, 2019 | March 2028 |
| NCT01809808 | Active, not recruiting | A Prospective Study of Outcome After Therapy for Acromegaly | September 2003 | June 2025 | |
| NCT00921609 | Active, not recruiting | Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly | June 2006 | April 2025 | |
| NCT01995734 | Approved for marketing | An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly | |||
| NCT00171730 | Completed | Phase 2 | An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly | August 24, 2004 | December 6, 2013 |
| NCT00171886 | Completed | Phase 4 | Octreotide Efficacy and Safety in First-line Acromegalic Patients | July 2002 | May 2006 |
| NCT00182091 | Completed | N/A | Effects of Growth Hormone Administration on Cardiovascular Risk in Cured Acromegalics With Growth Hormone Deficiency | August 2004 | December 2010 |
| NCT00210457 | Completed | Phase 3 | Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients | September 2000 | July 15, 2002 |
| NCT00216398 | Completed | Phase 4 | Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR | June 2004 | June 22, 2006 |
| NCT00225979 | Completed | Phase 3 | Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly | November 2002 | March 2005 |
| NCT00234520 | Completed | A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide | May 2003 | February 18, 2005 | |
| NCT00234572 | Completed | Phase 2/Phase 3 | Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly | May 2000 | January 3, 2003 |
| NCT00372697 | Completed | Phase 3 | Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly | December 2005 | October 2007 |
| NCT00376064 | Completed | Phase 4 | Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly | March 2006 | |
| NCT00383708 | Completed | Phase 3 | Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients | October 2006 | October 2008 |
| NCT00444873 | Completed | Phase 3 | Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly | January 2005 | January 2008 |
| NCT00446082 | Completed | Phase 1 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | June 2006 | November 2013 |
| NCT00447499 | Completed | Phase 3 | Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel | April 2007 | December 2008 |
| NCT00461149 | Completed | Phase 4 | Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly | January 1995 | December 2006 |
| NCT00461240 | Completed | Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States | June 2007 | December 2011 | |
| NCT00499993 | Completed | Phase 3 | Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly | January 2001 | May 2003 |
| NCT00500227 | Completed | Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery | September 2007 | July 2012 | |
| NCT00521300 | Completed | Phase 4 | Preoperative Octreotide Treatment of Acromegaly | September 1999 | May 2010 |
| NCT00531908 | Completed | N/A | Physiopathology of Sodium Retention in Acromegaly | September 2007 | December 2009 |
| NCT00552071 | Completed | Phase 4 | Ultrasound Guided Octreotide LAR Injection in Acromegaly | July 2007 | March 2014 |
| NCT00595140 | Completed | Phase 4 | Acute Application of Pegvisomant and Octreotide in Acromegaly | January 2008 | March 2008 |
| NCT00600886 | Completed | Phase 3 | Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly | February 11, 2008 | March 11, 2016 |
| NCT00615004 | Completed | Cardiovascular Outcome After Surgery or Somatostatin Analogues | January 1997 | December 2007 | |
| NCT00616408 | Completed | Prediction of Tumor Shrinkage in Acromegaly | January 1997 | December 2007 | |
| NCT00616551 | Completed | Phase 3 | Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients | April 2007 | February 2008 |
| NCT00627796 | Completed | Phase 4 | Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly | January 2003 | December 2007 |
| NCT00001860 | Completed | Phase 2 | Sandostatin LAR Depot vs. Surgery for Treating Acromegaly | August 1999 | July 2002 |
| NCT00642720 | Completed | Phase 4 | Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients | October 2006 | July 2007 |
| NCT00647179 | Completed | Substrate Metabolism and Insulin Sensitivity in Acromegalic Patients Before and After Treatment | February 2008 | December 7, 2016 | |
| NCT00652379 | Completed | N/A | Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients | June 2008 | May 2011 |
| NCT00658879 | Completed | Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan | August 7, 2007 | November 9, 2016 | |
| NCT00663000 | Completed | Glucose Tolerance in Acromegaly: The Influence of GH-excess on Glucose Metabolism and Insulin Resistance | April 2008 | December 2012 | |
| NCT00686348 | Completed | Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study | May 2008 | November 2015 | |
| NCT00690898 | Completed | Phase 3 | Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma | May 2008 | February 2012 |
| NCT00701363 | Completed | Phase 4 | Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects | October 2008 | May 2013 |
| NCT00703079 | Completed | Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly | January 1997 | June 2008 | |
| NCT00747500 | Completed | Non Interventional Post Marketing Programme in Acromegaly | July 2008 | March 2013 | |
| NCT00858143 | Completed | Non Interventional Study For Patients Treated With Somavert® | January 2004 | January 2008 | |
| NCT00913055 | Completed | Phase 2 | Open Label Study of Octreotide Implant in Patients With Acromegaly | February 2007 | May 2007 |
| NCT00915954 | Completed | N/A | Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) | December 2008 | June 2014 |
| NCT00934271 | Completed | Fractionated Stereotactic Radiotherapy in Patients With Acromegaly | January 2002 | January 2008 | |
| NCT00635765 | Completed | Phase 3 | Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients | October 2007 | June 2009 |
| NCT00001981 | Completed | The Treatment and Natural History of Acromegaly | October 2, 1991 | November 20, 2020 | |
| NCT00004332 | Completed | Study of the Effect of Growth Hormone-Releasing Hormone Antagonist on Growth Hormone Release in Acromegaly | May 1993 | ||
| NCT00068029 | Completed | Phase 4 | Pegvisomant And Sandostatin LAR Combination Study | October 2003 | May 2006 |
| NCT00068042 | Completed | Phase 4 | A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly | April 2003 | May 2006 |
| NCT00088582 | Completed | Phase 2 | Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients | March 2004 | |
| NCT00128232 | Completed | Phase 3 | Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients | December 2002 | |
| NCT00143416 | Completed | Phase 3 | Long Term Study With B2036-PEG | April 2004 | July 2007 |
| NCT00145405 | Completed | Phase 4 | Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction | September 2002 | December 2004 |
| NCT00149188 | Completed | Phase 4 | Somatuline Autogel: Acromegaly Self/Partner Injection Study | February 2004 | August 24, 2005 |
| NCT00151437 | Completed | Phase 4 | Canadian Pegvisomant Compassionate Study In Acromegalic Patients | November 2004 | April 2007 |
| NCT01014793 | Completed | Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients | May 2005 | December 2008 | |
| NCT01029275 | Completed | N/A | Somatostatin Analog Treatment of Acromegaly Before Pituitary Surgery : Comparison With Neurosurgery Alone | January 2005 | January 2012 |
| NCT01062529 | Completed | N/A | Peripheral Metabolic Effects of Somatostatin | October 2009 | February 2010 |
| NCT01137682 | Completed | Phase 3 | Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly | July 19, 2010 | February 28, 2017 |
| NCT01261000 | Completed | N/A | Tissue Biomarker for Pegvisomant Action | November 2010 | December 2013 |
| NCT01278342 | Completed | Phase 4 | Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients | September 2006 | November 2009 |
| NCT01302652 | Completed | Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment | February 2011 | February 2015 | |
| NCT01333384 | Completed | Study in Polish Acromegalic Patients Treated With Somatuline Autogel | October 2010 | June 2014 | |
| NCT01412424 | Completed | Phase 3 | Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly | March 2012 | May 2014 |
| NCT01471405 | Completed | One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma | January 2012 | August 2013 | |
| NCT01504399 | Completed | Rhinological Outcomes in Endonasal Pituitary Surgery | October 1, 2011 | December 9, 2015 | |
| NCT01568359 | Completed | Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors | December 2011 | August 2014 | |
| NCT01618513 | Completed | Phase 4 | Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target | June 2012 | January 2017 |
| NCT01673646 | Completed | Phase 2 | Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism | October 16, 2012 | April 10, 2017 |
| NCT01723748 | Completed | N/A | Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects | December 2012 | May 2015 |
| NCT01732406 | Completed | Acromegaly Treatment Quality of Life Study | January 2013 | December 19, 2016 | |
| NCT01794793 | Completed | Phase 4 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | June 10, 2013 | July 29, 2023 |
| NCT01819883 | Completed | Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly | April 2013 | March 30, 2016 | |
| NCT01840449 | Completed | Somatuline Predictive Factors in Acromegaly and NET | June 2012 | May 2017 | |
| NCT02012127 | Completed | Description of Sign-and-symptom Associations at Acromegaly Diagnosis. | September 2013 | June 2014 | |
| NCT02020967 | Completed | Programme of Acromegaly Screening in Patients With Associated Somatic Disorders | December 5, 2013 | September 15, 2015 | |
| NCT02060383 | Completed | Phase 4 | Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly | May 23, 2014 | March 26, 2018 |
| NCT02084095 | Completed | IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly | March 2014 | March 1, 2019 | |
| NCT02111044 | Completed | Phase 2 | Phase II Study With ITF2984 in Acromegalic Patients | April 2014 | February 2016 |
| NCT02152124 | Completed | Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism? | June 1, 2014 | August 31, 2017 | |
| NCT02217800 | Completed | Phase 2 | The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics | November 2013 | May 2016 |
| NCT02231593 | Completed | SAGIT for Classification of Patients With Acromegaly in Clinical Practice | February 2013 | May 2014 | |
| NCT02235987 | Completed | Phase 2 | Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients. | October 2012 | April 2014 |
| NCT02274311 | Completed | Phase 2 | Clomiphene Citrate for Treatment of Acromegaly | January 2011 | October 2014 |
| NCT02296216 | Completed | N/A | Late Effects of Radiosurgery on Acromegaly Study | February 16, 2015 | April 13, 2023 |
| NCT02299089 | Completed | Phase 2 | Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs) | January 2015 | June 2016 |
| NCT02354508 | Completed | Phase 3 | Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues | March 31, 2015 | September 27, 2018 |
| NCT02371057 | Completed | Acromegaly & Sleep Apnoea | November 24, 2014 | February 21, 2018 | |
| NCT02396953 | Completed | Phase 1/Phase 2 | Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly | March 2015 | November 28, 2017 |
| NCT02396966 | Completed | Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment. | December 2014 | May 2018 | |
| NCT02493517 | Completed | Phase 3 | Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly | October 2014 | February 16, 2017 |
| NCT02539927 | Completed | Validation Study of the SAGIT® Instrument in Acromegaly | July 2015 | September 3, 2018 | |
| NCT02685709 | Completed | Phase 3 | Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly | February 2016 | August 2021 |
| NCT02807233 | Completed | Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects | July 2016 | September 2017 | |
| NCT02934399 | Completed | Dynamic Hormone Diagnostics in Endocrine Disease | October 2016 | November 14, 2023 | |
| NCT02948322 | Completed | N/A | Cardiac (CMRI) Assessment of Acromegaly | December 2014 | February 28, 2019 |
| NCT02952885 | Completed | Phase 3 | Strict IGF-1 Control in Acromegaly | July 27, 2017 | May 7, 2020 |
| NCT03225040 | Completed | Bone MicroArchitecture in Acromegaly | August 3, 2016 | December 21, 2019 | |
| NCT03548415 | Completed | Phase 2 | Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands | September 13, 2018 | April 2, 2021 |
| NCT03613623 | Completed | Acromegaly: Patient And Physician Perspectives | July 2, 2018 | September 1, 2020 | |
| NCT03789656 | Completed | Phase 2 | An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) | January 15, 2019 | August 31, 2020 |
| NCT03792555 | Completed | Phase 2 | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) | December 18, 2018 | August 12, 2020 |
| NCT03849872 | Completed | Phase 1 | Single-dose Study to Evaluate the Absolute Bioavailability and Mass Balance of ONO-5788 | February 27, 2019 | April 2, 2019 |
| NCT03967249 | Completed | Phase 2 | Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands | July 25, 2019 | July 7, 2022 |
| NCT04076462 | Completed | Phase 3 | A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly | August 19, 2019 | May 2, 2023 |
| NCT04138537 | Completed | N/A | Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients | August 15, 2018 | January 30, 2020 |
| NCT04522180 | Completed | Phase 2 | A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly | January 4, 2021 | May 4, 2023 |
| NCT04844164 | Completed | Phase 1 | Vitamin D Metabolism in Patients With Endocrine Disorders | April 16, 2019 | June 1, 2021 |
| NCT05069324 | Completed | PegvisOMant and the Immune SystEm (PROMISE) | July 29, 2020 | June 15, 2023 | |
| NCT05752825 | Completed | Acromegaly: Balance, Falls and Fracture Risk | June 2, 2023 | May 15, 2024 | |
| NCT05761431 | Completed | Phase 1 | A Single-dose Study of Octreotide Injection in Healthy Adult Subjects | March 2, 2023 | June 28, 2023 |
| NCT01000090 | Completed | Surgical Versus Medical Treatment of Acromegaly | October 2009 | June 2011 | |
| NCT06372652 | Not yet recruiting | Phase 1 | A Phase 1 Study of TE-8214 Solution in Healthy Volunteers | May 2, 2024 | December 26, 2024 |
| NCT05298891 | Not yet recruiting | N/A | Hypoproteic Diet in Acromegaly | September 1, 2024 | March 1, 2026 |
| NCT06326853 | Not yet recruiting | Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models | July 2024 | December 2026 | |
| NCT03042026 | Recruiting | Developing a Simple Recognition System of Acromegaly | June 1, 2012 | June 1, 2027 | |
| NCT05964712 | Recruiting | Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional Study | June 18, 2019 | December 31, 2025 | |
| NCT05131100 | Recruiting | Korean Regulatory Post Marketing Surveillance for Somavert | July 13, 2022 | September 15, 2026 | |
| NCT03474601 | Recruiting | Seoul National University Pituitary Disease Cohort Study | March 15, 2015 | February 14, 2025 | |
| NCT05401084 | Recruiting | N/A | Diet in the Management of Acromegaly | September 20, 2024 | March 1, 2025 |
| NCT03158090 | Recruiting | The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research | December 15, 2017 | January 30, 2051 | |
| NCT06344650 | Recruiting | Cellular, Molecular and Clinical Determinants of Bone Strength in in Vivo and Human Models of GH Excess. Cross-sectional and Prospective Study | September 28, 2023 | July 2024 | |
| NCT06253897 | Recruiting | A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly | May 29, 2024 | August 30, 2024 | |
| NCT00461188 | Recruiting | Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA | March 2007 | April 2099 | |
| NCT01086982 | Suspended | Phase 1 | Pharmacodynamics Of Product Octreotide Acetate Lar 30 Mg Compared To Product Sandostatin LAR ® | March 2010 | May 2010 |
| NCT02020499 | Terminated | Predictive Factors Study | August 2014 | September 2015 | |
| NCT01861717 | Terminated | Phase 4 | A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. | May 2013 | January 2016 |
| NCT00765323 | Terminated | Phase 3 | Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly | September 2008 | June 2011 |
| NCT02698384 | Terminated | Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg | January 2016 | June 2016 | |
| NCT03571594 | Terminated | Phase 1 | A Four-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-5788 in Healthy Adult Volunteers | June 7, 2018 | May 16, 2019 |
| NCT01295060 | Terminated | Phase 3 | Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly | February 2011 | June 2012 |
| NCT00642421 | Terminated | Phase 3 | Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients | February 2008 | August 2009 |
| NCT01538966 | Terminated | N/A | Acromegaly Combination Treatment Study | March 29, 2012 | May 20, 2022 |
| NCT03045302 | Terminated | Phase 2 | Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly | January 26, 2017 | June 2, 2017 |
| NCT00994214 | Terminated | Phase 2 | Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly | October 2009 | February 2011 |
| NCT00242541 | Terminated | Phase 4 | Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas | March 2003 | |
| NCT04066569 | Unknown status | N/A | Reproducibility and Utility of OGTT in Acromegaly | September 10, 2019 | December 10, 2022 |
| NCT02403414 | Unknown status | Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation | March 2015 | February 2018 | |
| NCT02427295 | Unknown status | Phase 4 | Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues | March 2014 | December 2019 |
| NCT04529356 | Unknown status | N/A | The TMS Treatment for Postoperative Headache in GH Tumor | September 1, 2020 | September 30, 2022 |
| NCT02668172 | Unknown status | Phase 4 | Pasireotide LAR and Pegvisomant Study in Acromegaly | August 2015 | June 2017 |
| NCT01265121 | Unknown status | N/A | Sleep Apnea Syndrome on Acromegaly: Impact of the Treatment on the Carbohydrates Metabolism. | September 2009 | June 2011 |
| NCT04860037 | Unknown status | Micromegaly and Discrepancy Between Growth Hormone and IGF1 at the Diagnosis and Follow-up of Acromegalic Patients | January 1, 2010 | December 1, 2022 | |
| NCT01368133 | Unknown status | The Observational Study of Growth Hormone-secreting Pituitary Tumors | May 2011 | December 2013 | |
| NCT01371045 | Unknown status | Oral Glucose Tolerance Testing (OGTT) on Patients Taking Somatostatin Analogs | June 2011 | ||
| NCT01424241 | Unknown status | Phase 4 | Effects of Sandostatin LAR® in Acromegaly | August 2006 | August 2013 |
| NCT01612624 | Unknown status | Prospective Study on Changes in Acromegaly | May 2012 | ||
| NCT05149495 | Unknown status | Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery | October 1, 2021 | March 20, 2023 | |
| NCT03252353 | Unknown status | Phase 3 | Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly | September 1, 2017 | May 2022 |
| NCT03401008 | Unknown status | Buccodental Manifestations in Patients With Acromegaly | December 15, 2016 | March 30, 2019 | |
| NCT01752621 | Unknown status | Epidemiology of Acromegaly in Denmark 1991-2010 | February 2013 | March 2015 | |
| NCT03431727 | Unknown status | Acromegaly - Before and After Treatment | October 1, 2017 | December 1, 2022 | |
| NCT00916916 | Unknown status | Lanreotide Levels in Acromegaly | |||
| NCT01902420 | Unknown status | Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly | November 2012 | August 2014 | |
| NCT02005978 | Unknown status | Brain-gut Interaction in Irradiated Patients With Acromegaly | April 2013 | December 2017 | |
| NCT00315107 | Unknown status | Phase 2 | Estrogen Treatment in Acromegalic Women | May 2006 | August 2007 |
| NCT03673761 | Unknown status | Muscle in Acromegaly and Cushing's Syndrome | February 1, 2018 | January 31, 2020 | |
| NCT03710499 | Unknown status | N/A | Rehabilitation Program in Patients With Acromegaly | January 10, 2016 | October 10, 2019 |
| NCT02092129 | Unknown status | Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly. | September 2013 | December 2017 | |
| NCT02115906 | Unknown status | Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly | August 2014 | May 2018 | |
| NCT00005100 | Unknown status | Measurement of Outcome of Surgical Treatment in Patients With Acromegaly | September 1999 | ||
| NCT00552851 | Unknown status | Phase 4 | Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant | June 2006 | December 2010 |
| NCT04520646 | Unknown status | N/A | A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy | September 1, 2020 | August 31, 2022 |
| NCT00993356 | Unknown status | Phase 2 | Preoperative Lanreotide Treatment in Acromegalic Patients With Macroadenomas | January 2004 | December 2010 |
| NCT00517491 | Withdrawn | Phase 2 | Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG) | May 2008 | December 2008 |
| NCT04003519 | Withdrawn | Study to Predict Lanreotide-induced Disease Activity Normalization in Acromegaly | April 2020 | December 30, 2023 | |
| NCT00638287 | Withdrawn | Inter-Assay Growth Hormone and IGF-I Variability | November 2007 | January 2011 | |
| NCT05184231 | Withdrawn | Patient and Physician Survey on Satisfaction With Somatostatin Analogue (SSA) Injections in Acromegaly in China | February 13, 2023 | October 2023 |
- Disase is a (Disease Ontology)
- DOID:2444
- Cross Reference ID (Disease Ontology)
- GARD:5725
- Cross Reference ID (Disease Ontology)
- MESH:D000172
- Cross Reference ID (Disease Ontology)
- NCI:C84533
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:154698000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0001206
- OrphaNumber from OrphaNet (Orphanet)
- 963
- MeSH unique ID (MeSH (Medical Subject Headings))
- D000172